Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer
Metrics: PDF 2165 views | HTML 2189 views | ?
Rui Zhou1,*, Xiaoshu Zhou1,*, Zhongyuan Yin1, Jing Guo2, Ting Hu1, Shun Jiang3, Li Liu1, Xiaorong Dong1, Sheng Zhang1, Gang Wu1
1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Department of Oncology of The Affiliated Hospital of Qingdao University, Qingdao, China
3Department of Oncology, Second Xiangya Hospital of Central South University, Changsha, China
*These authors have contributed equally to this work
Gang Wu, e-mail: email@example.com
Keywords: miR-184, miR-574-5p, metastasis, prognosis, SCLC
Received: April 18, 2015 Accepted: November 06, 2015 Published: November 16, 2015
Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor that has an extremely poor clinical prognosis. Metastasis is the key event in SCLC progression, but its mechanism has not been fully elucidated. MicroRNAs (miRNAs) have been proven to participate in cancer processes, but their function in SCLC has not been thoroughly studied either. Here, we performed microarray and quantitative real-time PCR (qRT-PCR) analysesto identify the miRNAsassociated with metastasis and prognosis in SCLC as well as the correlation between serum and tissue. We also explored these miRNAs’ promising molecular mechanisms by 3′UTR reporter assay and immunoblotting. We showed thatmiR-184 significantly attenuated the metastasis of SCLC, whereas miR-574–5p enhanced it. Both miRNAs were found to participate in β-catenin signaling by suppressing protein tyrosine phosphatase receptor type U (PTPRU)orendothelial PAS domain protein 1 (EPAS1). Furthermore, miR-574–5p was verified as an independent prognostic risk factor for SCLC. Taken together, our findings providea comprehensive analysis of the miRNA expression pattern in SCLC and indicate that miRNAs may serve as potential therapeutic and prognostic predictors in SCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.